How to increase AAV production with a novel enhancer designed for use with any transfection reagent in any suspension HEK cell
Sep
5
2023
On demand

How to increase AAV production with a novel enhancer designed for use with any transfection reagent in any suspension HEK cell

Tuesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Sponsor
How to increase AAV production with a novel enhancer designed for use with any transfection reagent in any suspension HEK cell

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

With the success of cell and gene therapies and exponentially increasing demand, the second wave of viral vector manufacturing is focused on large-scale suspension cell culture. Upstream manufacturing processes for recombinant adeno-associated virus (AAV) and lentivirus (LV) are largely dependent on transient transfection of multiple plasmid DNA constructs encoding essential viral proteins. To produce the virus needed for these therapies, processes must be adapted to bioreactor scale for cGMP production.

In response to this need, Mirus Bio has already established a novel transfection reagent that increases AAV and LV titers 2-10-fold over existing technologies. The focus of this talk is the development of an enhancer that further increases AAV production by up to 2-3-fold with any transfection reagent, in any HEK 293 cell type, and for any serotype. Important characteristics were considered during reagent and enhancer development to ensure scalability, straightforward optimization, and seamless adoption within AAV manufacturing.

  • Learn to increase AAV production across multiple transfection reagents
  • Assess the impact of the novel enhancer across multiple serotypes, including AAV2, AAV5, AAV8, and AAV9 (based on data from both internal and customer testing)
  • Review the recommended protocol and amounts of enhancer to use within AAV workflows
  • Understand how higher AAV production leads to lower costs per dose
  • What support is available for evaluating and using the enhancer in your process
Leisha Kopp
Leisha Kopp
Senior Field Applications Scientist at Mirus Bio
Leisha Kopp is a Senior Field Applications Scientist at Mirus Bio, a company committed to equipping biopharmaceutical innovators with next generation transfection solutions for all cell culture applications. Leisha has 20 years of molecular biology and mammalian cell culture experience in industrial labs and has worked extensively with an array of primary and immortalized mammalian cells. Her combined bench and biopharma knowledge enables support of scientists in all stages of the drug discovery process to develop optimized and scalable processes that deliver complex therapies to patients more quickly. Leisha is a graduate of the University of Wisconsin-Madison, with key interests in viral vector manufacturing and gene therapy.

SPEAKERS

Leisha Kopp
Leisha Kopp
Senior Field Applications Scientist at Mirus Bio